Skip to Content
Biotechnology and health

Y Combinator Will Give You $1 Million to Try to Cure Aging

January 11, 2018

The famed startup incubator Y Combinator put out a call for companies that want to increase human longevity and “health span.”

Who they want: Founders with new ideas for treating old-age diseases like Alzheimer’s, “but we will also consider more radical anti-aging schemes,” YC president Sam Altman told MIT Technology Review

Why longevity? Efforts to stop old age don’t actually get funded much. “My sense is that economic incentives of drugs companies are screwed up” says Altman. “I don’t think we have enough people saying, How can we make a lot of people a lot heathier?” 

The deal: Longevity startups get $500,000 to $1 million in exchange for a 20 percent stake, lab space, and advice (quite a bit more than the $120,000 software companies get if they’re picked for the incubator. But hey, biology is more expensive). They will travel to San Francisco to join the next three-month “class" of startups, which starts in June.

Big bio returns? Y Combinator started accepting biology companies in 2014. One of them, Ginkgo, has gone on to raise hundreds of millions more to fund its organism-hacking business. As for others, Altman says he’s not worried about getting his money back: “You could make a pill that added two years to a person’s life that would be a $100 billion company.”

Deep Dive

Biotechnology and health

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

Some deaf children in China can hear after gene therapy treatment

After deafness treatment, Yiyi can hear her mother and dance to the music. But why is it so noisy at night?

Scientists just drafted an incredibly detailed map of the human brain

A massive suite of papers offers a high-res view of the human and non-human primate brain.

Three people were gene-edited in an effort to cure their HIV. The result is unknown.

CRISPR is being used in an experimental effort to eliminate the virus that causes AIDS.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.